Stifel Financial Corp Trims Stock Position in Kenvue Inc. (NYSE:KVUE)

Stifel Financial Corp lowered its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 16.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 802,778 shares of the company's stock after selling 155,457 shares during the quarter. Stifel Financial Corp's holdings in Kenvue were worth $17,139,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC raised its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after acquiring an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE stock traded up $0.18 during mid-day trading on Thursday, hitting $23.78. The company had a trading volume of 4,350,614 shares, compared to its average volume of 17,007,513. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $45.62 billion, a P/E ratio of 44.86, a P/E/G ratio of 2.62 and a beta of 1.02. The stock's 50 day moving average price is $23.07 and its 200-day moving average price is $22.47. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.45%. The ex-dividend date is Wednesday, May 14th. Kenvue's payout ratio is currently 154.72%.

Analysts Set New Price Targets

Several research analysts recently issued reports on KVUE shares. Barclays cut their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, April 14th. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler increased their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Finally, Citigroup lifted their price target on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research note on Monday, April 14th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.